PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cmajCMAJ Information for AuthorsCMAJ Home Page
 
CMAJ. 2010 May 18; 182(8): 806.
PMCID: PMC2871214

Correction: Research

The article “A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview”1 published Nov. 24, 2009, contained incorrect information, including several numbers needed to treat and 95% confidence intervals in Table 2 and some numbers in Table 3. As well, in Figure 2, the dotted line should go through 1.0, not to the right of it, and in Figure 3, Etanercept, I2should be 0% not 94%. In the Methods section, the following sentence should have been added: “Studies using the recommended, approved doses of biologics were included in this network analysis.” In the subsection “Number needed to treat,” the third sentence should read: “The numbers needed to treat for benefit were 3 (95% CI 3–5) for etanercept, 4 (95% CI 3–6) for adalimumab, 4 for (95% CI 3–8) for rituximab, 5 (95% CI 3–10) for abatacept and 5 (95% CI 3–18) for infliximab.”

A corrected PDF is available online at www.cmaj.ca/cgi/data/cmaj.091391/DC2/1.

REFERENCE

1. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181:787–96. [PMC free article] [PubMed]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association